Current Oncology

Scope & Guideline

Unlocking Knowledge, Transforming Oncology

Introduction

Explore the comprehensive scope of Current Oncology through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Current Oncology in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1198-0052
PublisherMDPI
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationCURR ONCOL / Curr. Oncol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND

Aims and Scopes

Current Oncology is dedicated to advancing knowledge and practice in the field of oncology through the publication of high-quality research and reviews. The journal aims to cover a broad spectrum of topics related to cancer, including clinical, experimental, and translational research, providing a comprehensive resource for oncologists, researchers, and healthcare professionals.
  1. Clinical Oncology:
    Focuses on the clinical aspects of cancer treatment, including chemotherapy, radiotherapy, and surgical interventions, emphasizing evidence-based practices and patient outcomes.
  2. Translational Research:
    Highlights studies that bridge laboratory research and clinical application, exploring how scientific discoveries can inform and improve cancer treatment.
  3. Epidemiology and Public Health:
    Examines cancer incidence, risk factors, and outcomes across populations, addressing disparities in cancer care and promoting public health initiatives.
  4. Innovative Therapies:
    Covers emerging treatments such as immunotherapy, targeted therapy, and novel drug combinations, aiming to provide insights into the latest advancements in cancer management.
  5. Patient-Centered Care:
    Focuses on the psychosocial aspects of cancer care, including quality of life, survivorship, and the experiences of patients and caregivers in navigating the healthcare system.
  6. Health Economics and Policy:
    Investigates the economic implications of cancer treatments and policies, aiming to inform cost-effective strategies for cancer care delivery.
Current Oncology shows a dynamic evolution in its research focus, with several emerging themes reflecting the latest advancements and challenges in oncology. These trends highlight the journal's commitment to addressing contemporary issues in cancer care.
  1. Immunotherapy and Combination Therapies:
    A significant increase in research dedicated to immunotherapy, particularly in combination with other treatments, indicates a shift towards personalized and effective cancer treatments.
  2. Real-World Evidence and Outcomes Research:
    A growing emphasis on real-world evidence studies reflects a need to understand treatment effectiveness and patient experiences outside of clinical trial settings.
  3. Patient-Reported Outcomes and Quality of Life:
    An increasing focus on patient-reported outcomes and quality of life assessments suggests a recognition of the importance of holistic care in oncology.
  4. Telehealth and Virtual Care:
    The COVID-19 pandemic has accelerated the integration of telehealth in cancer care, leading to a rise in studies exploring its effectiveness and patient acceptance.
  5. Health Equity and Disparities:
    Emerging research addressing health disparities and access to care for marginalized populations highlights a critical need for equitable cancer treatment strategies.
  6. Genomic Profiling and Precision Medicine:
    The trend towards genomic profiling and precision medicine is prominent, with increasing studies examining the role of biomarkers in tailoring cancer therapies.

Declining or Waning

While Current Oncology continues to expand its focus on emerging and relevant areas in cancer research, certain themes appear to be declining in prominence. These waning scopes indicate a shift in research priorities and interests within the field.
  1. Traditional Chemotherapy Regimens:
    As newer therapies such as immunotherapy and targeted treatments gain popularity, traditional chemotherapy regimens are receiving less emphasis in recent publications.
  2. Single-Institution Studies:
    There is a noticeable decline in the publication of studies from single institutions, with a growing preference for multicenter trials that provide broader insights into treatment outcomes.
  3. Basic Science Research:
    Research focused solely on basic science and preclinical models is becoming less frequent, as the field shifts towards studies that emphasize translational and clinical relevance.
  4. Radiation Therapy Alone:
    The exploration of radiation therapy as a standalone treatment is decreasing, likely due to the increasing integration of combined modalities with systemic therapies.
  5. Conventional Screening Methods:
    Interest in traditional cancer screening methods is waning in favor of innovative approaches such as genomic screening and personalized medicine.

Similar Journals

South Asian Journal of Cancer

Uniting expertise to combat cancer in South Asia.
Publisher: GEORG THIEME VERLAG KGISSN: 2278-330XFrequency: 4 issues/year

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

ANNALS OF ONCOLOGY

Leading the charge in cancer care and clinical practice.
Publisher: ELSEVIERISSN: 0923-7534Frequency: 12 issues/year

ANNALS OF ONCOLOGY, published by Elsevier, stands as a premier journal in the field of oncology, hematology, and general medicine, with a notable impact factor that underscores its significance in advancing cancer research and clinical practice. Established in 1990, this journal has become a highly respected source of information, consistently ranked in the Q1 category in its respective fields, showcasing its influence and credibility (Rank #4/404 in Oncology and Rank #2/137 in Hematology as per Scopus rankings). With a focus on innovative therapies, clinical trials, and emerging research, ANNALS OF ONCOLOGY serves as an essential resource for researchers, clinicians, and students dedicated to unraveling the complexities of cancer treatment and care. Although offering restricted access options, its impactful studies and discoveries continue to shape the future of oncology.

BRITISH JOURNAL OF CANCER

Transforming Cancer Care with Cutting-Edge Discoveries.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Revista Colombiana de Cancerologia

Innovating Cancer Care: Insights from Colombia
Publisher: INST NACIONAL CANCEROLOGIAISSN: 0123-9015Frequency: 4 issues/year

Revista Colombiana de Cancerologia is a premier journal dedicated to advancing the field of oncology in Colombia and beyond. Published by the Instituto Nacional de Cancerología, this journal serves as a vital platform for the dissemination of high-quality research, comprehensive reviews, and innovative methodologies pertinent to cancer research and treatment. With an ISSN of 0123-9015 and E-ISSN 2346-0199, it aims to engage a diverse audience, including researchers, healthcare professionals, and students, fostering collaboration and knowledge sharing within the oncology community. Although specific metrics such as impact factors and H-index are currently unavailable, the journal is committed to maintaining high academic standards and encouraging open access to vital oncological insights. The Revista Colombiana de Cancerologia is positioned as an essential resource for those interested in the latest advancements in cancer care, prevention, and research methodologies, making significant contributions to the understanding and management of cancer.

LANCET ONCOLOGY

Advancing cancer research for a healthier tomorrow.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

CLINICAL ONCOLOGY

Fostering Collaboration for Breakthroughs in Cancer Treatment
Publisher: ELSEVIER SCIENCE LONDONISSN: 0936-6555Frequency: 6 issues/year

Clinical Oncology is a prestigious peer-reviewed journal published by Elsevier Science London, focusing on the dynamic fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an impressive impact factor reflecting its high-quality research contributions, the journal is ranked in the second quartile for oncology and the first quartile for radiology, underscoring its importance in advancing clinical knowledge and practice. Established in 1975, Clinical Oncology offers researchers, healthcare professionals, and students robust access to cutting-edge studies, reviews, and clinical trials that drive innovation and improve patient care. Based in the United Kingdom, the journal plays a vital role in disseminating significant findings, fostering collaboration, and enhancing education in the biosciences, particularly for those committed to addressing the challenges in cancer treatment and diagnostics. Given its rigorous selection criteria and broad readership, Clinical Oncology remains an essential resource for anyone dedicated to the fields of oncology and radiology.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Navigating the Landscape of Cancer Trials
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0277-3732Frequency: 12 issues/year

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.

Turk Onkoloji Dergisi-Turkish Journal of Oncology

Connecting researchers to transform cancer treatment and prevention.
Publisher: KARE PUBLISSN: 1300-7467Frequency: 4 issues/year

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.

International Journal of Clinical Oncology

Empowering Oncology Research for Tomorrow
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

Clinical Genitourinary Cancer

Leading the charge in urological research excellence.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.